Fenster schließen  |  Fenster drucken

Auch das nächste Votum steht auf "Halten":


http://www.americanconsumernews.com/2011/01/zacks-investment…

Zacks Investment Research Analysts Give Cytokinetics, Inc. (NASDAQ: CYTK) a “Neutral” Rating
January 3rd, 2011 • Related • Filed Under • by ACN Staff
Filed Under: Stock Market News

Zacks Investment Research research analysts reiterated a “neutral” rating for shares of Cytokinetics, Inc. (NASDAQ: CYTK) in a research note issued to investors on Tuesday.

Cytokinetics, Inc. (NASDAQ: CYTK)’s stock opened at 2.09 on Monday. Cytokinetics, Inc. has a 52 week range of $2.01 to $3.78. The stock’s 50-day moving average is $2.25 and its 200-day moving average is $2.42. Analysts predict on average that Cytokinetics, Inc. will post $-0.20 earnings per share next quarter. The company has a market cap of $137.7 million and a P/E (price-to-earnings ratio) of N/A.
 
aus der Diskussion: ALS - Biotech machts möglich?
Autor (Datum des Eintrages): Karl79  (03.01.11 18:49:08)
Beitrag: 7 von 9 (ID:40791463)
Alle Angaben ohne Gewähr © wallstreet:online